ACTUATE THERAPEUTICS, INC.

Listed Company

ACTUCIK 0001652935NasdaqEmerging GrowthPharmaceutical PreparationsDelawareFY ends Dec 31

Period

FY 2025

Revenue

—

Net Income

$-22.23M

Total Assets

$14.04M

Equity

$7.92M

Shares Out

23.71M

Op. Cash Flow

$-19.21M

Business

ACTUATE THERAPEUTICS, INC. is a clinical-stage biopharmaceutical company developing therapies for difficult-to-treat cancers through inhibition of glycogen synthase kinase-3 (GSK-3). Its main product candidates are elraglusib formulations, including an intravenous Elraglusib Injection and an Elraglusib Oral Tablet, being evaluated as single agents and in combination with standard chemotherapies. The company’s activities center on clinical development programs and investigator-initiated trials focused on metastatic pancreatic ductal adenocarcinoma, refractory pediatric malignancies including Ewing sarcoma, and other oncology indications, supported by licensed intellectual property. It conducts clinical trials primarily in the United States with academic and industry collaborations, relies on third-party manufacturing, and intends to pursue regulatory approvals and commercialization in the U.S. and other jurisdictions.

Summary from filing dated 2025-03-13

Financials

Consolidated Statement of Income

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31
Research and development	10	19	22
General and administrative	12	6	3
Total operating expenses	22	25	25
Loss from operations	−22	−25	−25
Change in estimated fair value of warrant liability	0	−78,903	−79,822
Gain on settlement of warrants	0	343,240	0
Loss on issuance of related party convertible notes payable at fair value	0	−400,000	0
Change in estimated fair value of related party convertible notes payable	0	−2	0
Interest expense	−20,250	−18,717	−43,641
Interest income	287,710	222,293	352,672
Total other income (expense), net	267,460	−2	229,209
Net loss	−22	−27	−25
Weighted-average shares of common stock outstanding, basic	21	8	1
Weighted-average shares of common stock outstanding, diluted	21	8	1
Net loss per share attributable to common stockholders, basic	−1.06	−3.26	−17.24
Net loss per share attributable to common stockholders, diluted	−1.06	−3.26	−17.24

Consolidated Balance Sheet

As of · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31
Cash and cash equivalents	13	9	3	—
Prepaid assets and other current assets	483,996	566,278	36,907	—
Total current assets	14	9	3	—
Deferred offering costs and other assets	392,491	110,548	0	—
Total assets	14	9	3	—
Accounts payable	2	2	3	—
Other accrued expenses	4	6	3	—
Accrued compensation	588,304	888,449	277,500	—
Accrued interest, current	27,018	70,957	0	—
Total current liabilities	6	9	7	—
Accrued interest, less current portion	0	6,768	—	—
License payable	404,991	404,991	—	—
Total long-term liabilities	404,991	411,759	2	—
Total liabilities	6	9	8	—
Commitments and contingencies (Note 6)	—	—	—	—
Preferred stock, $0.000001 par value, 10,000,000 shares authorized, no shares issued or outstanding	0	0	0	—
Common stock, $0.000001 par value, 200,000,000 shares authorized, 23,245,203 and 19,531,636 shares issued and outstanding at December 31, 2025 and 2024, respectively	23	20	2	—
Additional paid-in capital	163	132	5	—
Accumulated deficit	−155	−132	−105	—
Total stockholders equity	8	104,186	−100	−75
Total liabilities and stockholders equity	14	9	3	—

Consolidated Statement of Cash Flows

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31
Stock-based compensation expense	6	2	423,539
Gain on settlement of warrant liability	0	−343,240	0
Loss on issuance of related party convertible notes payable at fair value	0	400,000	0
Change in estimated fair value of related party convertible notes payable	0	2	0
Interest accrued on license payable	20,250	18,641	—
Prepaid assets and other current assets	82,282	−529,371	−3,161
Other assets	110,548	−110,548	0
Accounts payable	−512,536	−2	1
Accrued compensation	−300,145	610,949	145,467
Accrued interest	−70,957	−70,957	0
Other accrued expenses	−2	3	1
Net cash used in operating activities	−19	−22	−22
Proceeds from issuance of shares of common stock under underwritten public offering, net of underwriting discounts and offering costs	16	0	—
Proceeds from issuance of shares of common stock under June 2025 Private Placement, net	5	0	—
Proceeds from issuance of shares of common stock under the Committed Equity Facility, net	4	0	—
Proceeds from the exercise of stock options	34,115	0	—
Proceeds from initial public offering, net of underwriting discounts and commissions	0	24	0
Payment of offering costs related to initial public offering	0	−2	0
Proceeds from issuance of related party short-term loan	0	200,000	0
Payment of related party short-term loan	0	−200,000	0
Proceeds from issuances of related party convertible notes payable	0	6	0
Net cash provided by financing activities	24	28	4
Net change in cash and cash equivalents	5	6	−17
Cash paid for interest	70,957	71,033	0
Cash paid for income taxes	800	800	0
Conversion of redeemable convertible preferred stock into common stock upon initial public offering	0	94	0
Reclassification of warrant liability to equity upon exchange of not in-the-money Series B and Series C Redeemable Convertible Preferred Stock Warrants for warrants to purchase common stock	0	485,172	0
Exercise of in-the-money warrants to purchase redeemable convertible preferred stock and conversion into common stock upon initial public offering	0	238,540	0
Conversion of related party convertible notes payable into common stock upon initial public offering	0	8	0
Deferred offering costs, unpaid and accrued	115,537	0	—
Deferred offering costs charged against Committed Equity Facility	25,871	0	—

Filings

Filing historySign up free to browse every 10-K, 10-Q, 8-K, and proxy this filer has submitted to the SEC.Sign up free · Upgrade to Pro

Material Events

Material EventsTrack every 8-K filing and material event — AI-summarized, timelined, and alertable.Sign up free · Upgrade to Pro

Insiders

Insider ActivitySee executive buy/sell windows and insider trade activity over rolling 30/90/365-day windows.Sign up free · Upgrade to Pro

Institutional Holders

Institutional HoldersSee which funds hold this stock and track position changes quarter over quarter.Sign up free · Upgrade to Pro